Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: A randomized, double‐blind trial

Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: A randomized, double‐blind trial

Abstract MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta®). This study was designed primarily to compare the immunogenicity of MSB11455 and Neulasta®. As secondary objectives, the safety and tolerability of MSB11455 and Neulasta® were also compared. Heal...

Full description

Bibliographic Details
Main Authors: Chris Wynne, Christian Schwabe, Emmanuelle Vincent, Armin Schueler, Janka Ryding, Martin Ullmann, Vishal Ghori, Radmila Kanceva, Michael Stahl
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Pharmacology Research & Perspectives
Subjects:
antidrug antibodies
immunogenicity
MSB11455
pegfilgrastim
safety
tolerability
Online Access:https://doi.org/10.1002/prp2.578

Internet

https://doi.org/10.1002/prp2.578

Similar Items